High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy

Cancer Genetics

Volumn 204, Issue 3, 2011, Pages 129-137

  Kreisel, F ^a   Kulkarni, S ^a   Kerns, R T ^a   Hassan, A ^a   Deshmukh, H ^a   Nagarajan, R ^a   Frater, J L ^a   Cashen, A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACGH; Chemo sensitive; Chemoresponsive; Copy number alterations; DLBCL

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CDKN2A GENE; CDKN2B GENE; CHEMOSENSITIVITY; CHROMOSOME 12Q; CHROMOSOME 14P; CHROMOSOME 16P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 22Q; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; PRIORITY JOURNAL; RUNX3 GENE; TUMOR SUPPRESSOR GENE; DOSE RESPONSE; DRUG RESISTANCE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETICS; METHODOLOGY; MIDDLE AGED; PREDICTIVE VALUE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENES, P16; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 79960662893     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2010.12.010     Document Type: Article

References (30)

1. Stein H., Warnke R.A., Chan W.C., et al. Diffuse large B-cell lymphoma, not otherwise specified. Tumours of hematopoietic and lymphoid tissues 2008, 233-237. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. De Paepe P., De Wolf-Peeters Diffuse large B-cell lymphomas: a heterogenous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007, 21:37-43.
3. Gurbaxani S., Anastasi J., Hyek E. Diffuse large B-cell lymphoma - more than a diffuse collection of large B cells. Arch Pathol Lab Med 2009, 133:1121-1134.
4. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
5. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002, 346:1937-1947. Lymphoma/Leukemia Molecular Profiling Project.
6. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
7. Muris J.J.F., Ylstra B., Cillessen S.A.G.M., et al. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphoma. Br J Hematol 2006, 136:38-47.
8. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
9. Muris J.J.F., Meijer C.J.L.M., Ossenkoppele G.J., et al. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. Hematol Oncol 2006, 24:97-104.
10. Georgakis G.V., Li Y., Humphreys R., et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Hematol 2005, 130:501-510.
11. Gascoyne R.D., Adomat S.A., Krajewski S., et al. Prognostic significance of BCL-2 protein expression and BCL-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251.
12. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
13. Quesnel B., Preudhomme C., Philippe N., et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995, 85:657-663.
14. Elenitoba-Johnson K.S.J., Gascoyne R.D., Lim M.S., et al. Homozygous deletions at chromosome 9p21 involving the p16 and p15 are associated with the histologic progression in follicle center lymphoma. Blood 1998, 91:4677-4685.
15. Schwaenen C., Viardot A., Berger H., et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes, Chromosomes & Cancer 2009, 48:39-54. for the Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe.
16. Jardin F., Picquenot J.-M., Parmentier F., et al. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. Br J Haematol 2009, 146:607-618.
17. Tagawa H., Tsuzuki S., Suzuki R., et al. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res 2004, 64:5948-5955.
18. Chen W., Houldsworth J., Olshen A.B., et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 2006, 107:2477-2485.
19. Tagawa H., Suguro M., Tsuzuki S., et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005, 106:1770-1777.
20. Belaud-Rotureau M.-A., Marietta V., Vergier B., et al. Inactivation of p16 INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. Virchows Arch 2008, 452:607-620.
21. INK4B in non-Hodgkin's lymphomas. Blood 1995, 4:1534-1539.
22. INK4A gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998, 8:2977-2984.
23. Lowe S.W., Sherr C.J. Tumor suppression by Inka-Arf: progress and puzzles. Curr Opin Genet Dev 2003, 13:77-83.
24. Savola S., Nardi F., Scotland K., et al. Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogene Genome Res 2007, 119:21-26.
25. Perez-Rosado A., Artiga M.J., Vargiu P., et al. BCL-6 represses NFκB activity in diffuse large B-cell lymphomas. J Pathol 2008, 214:498-507.
26. Lam L.T., Wright G., Davis R.E., et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008, 111:3701-3713.
27. Niu H., Ye B.H., Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes & Development 1998, 12:1953-1961.
28. Steinbach D., Gillet J.P., Sauerbrey A., et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006, 12:4357-4363.
29. Matsuo K, Hamajima N, Suzuki R, et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol;77:3513-3557.
30. Gemmati D., Ongaro A., Scapoli D.L., et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol Biomarkers Prev 2004, 13:787-794.